CN1384825A - 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 - Google Patents
亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 Download PDFInfo
- Publication number
- CN1384825A CN1384825A CN00815079A CN00815079A CN1384825A CN 1384825 A CN1384825 A CN 1384825A CN 00815079 A CN00815079 A CN 00815079A CN 00815079 A CN00815079 A CN 00815079A CN 1384825 A CN1384825 A CN 1384825A
- Authority
- CN
- China
- Prior art keywords
- tetrahydrochysene
- naphthyl
- pentamethyl
- group
- thiazolidinedione
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/40—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15167099P | 1999-08-31 | 1999-08-31 | |
US60/151,670 | 1999-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1384825A true CN1384825A (zh) | 2002-12-11 |
Family
ID=22539773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00815079A Pending CN1384825A (zh) | 1999-08-31 | 2000-08-31 | 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 |
Country Status (23)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432544A (zh) * | 2011-11-17 | 2012-05-02 | 天津医科大学 | 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用 |
CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2,4-二酮在制备ppar激动剂中的应用 |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1214305A1 (en) * | 1999-08-31 | 2002-06-19 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
US6620830B2 (en) | 2000-04-21 | 2003-09-16 | Pfizer, Inc. | Thyroid receptor ligands |
EP1148054B1 (en) * | 2000-04-21 | 2005-11-23 | Pfizer Products Inc. | Thyroid receptor ligands |
US6768008B2 (en) | 2000-04-24 | 2004-07-27 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6958355B2 (en) | 2000-04-24 | 2005-10-25 | Aryx Therapeutics, Inc. | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
US6680387B2 (en) | 2000-04-24 | 2004-01-20 | Aryx Therapeutics | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis |
AU2001294673A1 (en) | 2000-09-21 | 2002-04-02 | Aryx Therapeutics | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, andatherosclerosis |
GB0029125D0 (en) * | 2000-11-29 | 2001-01-10 | Specialistkliniken I Varberg H | Novel treatment |
JP2005506290A (ja) * | 2001-03-07 | 2005-03-03 | マキシア・ファーマシューティカルズ・インコーポレイテッド | 癌および他の増殖性疾患を処置するための複素環式誘導体 |
WO2002072543A2 (en) * | 2001-03-08 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Rxr activating molecules |
CA2340824A1 (en) * | 2001-03-14 | 2002-09-14 | Ibm Canada Limited-Ibm Canada Limitee | Method and system for application behavior analysis |
US6838442B2 (en) * | 2001-04-04 | 2005-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators |
US20030045553A1 (en) * | 2001-04-04 | 2003-03-06 | Bussolari Jacqueline C. | Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
JP2005500379A (ja) * | 2001-08-17 | 2005-01-06 | インサイト サンディエゴ インコーポレーテッド | 異脂肪血症および高コレステロール血症を治療するオキシム誘導体 |
JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環 |
JP2005516908A (ja) | 2001-11-30 | 2005-06-09 | ザ バーナム インスティチュート | 癌細胞におけるアポトーシスの誘導 |
US7102000B2 (en) * | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
CA2486138A1 (en) * | 2002-05-17 | 2003-11-27 | Qlt Inc. | Methods of using thiazolidinedithione derivatives |
FR2845383B1 (fr) * | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
FR2845384B1 (fr) * | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
FR2845385B1 (fr) * | 2002-10-04 | 2004-12-31 | Fournier Lab Sa | Composes derives de la 2-thiohydantoine et leur utilisation en therapeutique |
AU2003279442A1 (en) * | 2002-10-04 | 2004-04-23 | Laboratoires Fournier S.A. | 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes |
US6794401B2 (en) * | 2003-01-17 | 2004-09-21 | Bexel Pharmaceuticals, Inc. | Amino acid phenoxy ethers |
US7781464B2 (en) * | 2003-01-17 | 2010-08-24 | Bexel Pharmaceuticals, Inc. | Heterocyclic diphenyl ethers |
US7521465B2 (en) * | 2003-01-17 | 2009-04-21 | Bexel Pharmaceuticals, Inc. | Diphenyl ether derivatives |
US20050014767A1 (en) * | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
US20060210568A1 (en) * | 2003-03-07 | 2006-09-21 | Ginette Serrero | Methods and compositions for cancer treatment |
US20050038098A1 (en) * | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
WO2005012243A2 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted indole-o-glucosides |
CA2549022A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides |
AU2004261660A1 (en) | 2003-08-01 | 2005-02-10 | Janssen Pharmaceutica N.V. | Substituted fused heterocyclic C-glycosides |
EA010655B1 (ru) | 2003-08-01 | 2008-10-30 | Янссен Фармацевтика Н.В. | Замещенные индазол-о-глюкозиды |
US7087576B2 (en) * | 2003-10-07 | 2006-08-08 | Bexel Pharmaceuticals, Inc. | Dipeptide phenyl ethers |
WO2005035551A2 (en) | 2003-10-08 | 2005-04-21 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
US7122700B2 (en) * | 2004-07-30 | 2006-10-17 | Xerox Corporation | Arylamine processes |
WO2006096398A2 (en) * | 2005-03-03 | 2006-09-14 | Smithkline Beecham Corporation | Medicaments |
JP2009513570A (ja) | 2005-09-30 | 2009-04-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 異常脂血症、高コレステロール血症及び糖尿病の処置のためのrxrアゴニストとしての複素環式アミド誘導体 |
EP1951707A1 (en) | 2005-11-01 | 2008-08-06 | Janssen Pharmaceutica N.V. | Substituted pyrrolones as allosteric modulators of glucokinase |
CA2627892A1 (en) | 2005-11-01 | 2007-05-10 | Janssen Pharmaceutica N.V. | Substituted dihydroisoindolones as allosteric modulators of glucokinase |
CN101311167B (zh) * | 2007-05-25 | 2011-04-06 | 天津药物研究院 | 1-苯基咪唑烷-2,4-二酮类衍生物及其用途 |
EP2155643B1 (en) | 2007-06-08 | 2016-08-10 | MannKind Corporation | Ire-1a inhibitors |
JP2010539087A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | タデ科ファミリーのダイオウのエストロゲン性抽出物およびその使用 |
US20110263664A1 (en) * | 2007-11-15 | 2011-10-27 | Musc Foundation For Research Development | Inhibitors of PIM-1 Protein Kinases, Compositions and Methods for Treating Prostate Cancer |
CN103351390A (zh) | 2007-11-21 | 2013-10-16 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4 抑制剂 |
EP2254576B1 (en) * | 2008-02-22 | 2013-08-28 | The Ohio State University Research Foundation | Androgen receptor-ablative agents |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US20100331315A1 (en) * | 2009-06-18 | 2010-12-30 | Mustapha Haddach | Rhodanines and related heterocycles as kinase inhibitors |
JP5847085B2 (ja) | 2009-10-09 | 2016-01-20 | ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション | チアゾリジンジオンエネルギー制限模倣剤 |
US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
US9623015B2 (en) | 2012-11-05 | 2017-04-18 | Commissariat À L'energie Atomique Et Aux Energies Alternatives (Cea) | Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a STAT5 antagonist, preferably a thiazolidinedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse |
CA3093445A1 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | Aminopyrazine diol compounds as pi3k-.gamma. inhibitors |
US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
AU2022249065A1 (en) * | 2021-04-01 | 2023-11-02 | Aclipse Two Inc. | Treatment of kidney diseases |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051842A (en) * | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
DE2626348C3 (de) * | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
JPS5538359A (en) * | 1978-09-12 | 1980-03-17 | Hamari Yakuhin Kogyo Kk | Preparation of 2-(3-benzoylphenyl)-propionic acid |
US4383529A (en) * | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
IL72684A (en) * | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
US4931279A (en) * | 1985-08-16 | 1990-06-05 | Bausch & Lomb Incorporated | Sustained release formulation containing an ion-exchange resin |
US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
US4668506A (en) * | 1985-08-16 | 1987-05-26 | Bausch & Lomb Incorporated | Sustained-release formulation containing and amino acid polymer |
CA1325222C (en) * | 1985-08-23 | 1993-12-14 | Lederle (Japan), Ltd. | Process for producing 4-biphenylylacetic acid |
DE3874257T2 (de) * | 1987-03-11 | 1993-02-11 | Kanegafuchi Chemical Ind | Hydroxystyren-derivate. |
JPS63230689A (ja) | 1987-03-18 | 1988-09-27 | Tanabe Seiyaku Co Ltd | ベンゾオキサジン誘導体 |
FI91869C (fi) | 1987-03-18 | 1994-08-25 | Tanabe Seiyaku Co | Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi |
US5330998A (en) * | 1988-03-08 | 1994-07-19 | Pfizer Inc. | Thiazolidinedione derivatives as hypoglycemic agents |
US5223522A (en) * | 1988-03-08 | 1993-06-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
IE62214B1 (en) * | 1988-05-25 | 1995-01-11 | Warner Lambert Co | Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents |
JP2671962B2 (ja) * | 1991-07-22 | 1997-11-05 | ファイザー・インコーポレーテッド | キラルチアゾリジン−2,4−ジオン誘導体の合成における中間体の製造方法 |
DE10199033I2 (de) | 1992-04-22 | 2003-01-09 | Ligand Parmaceuticals Inc | Retinoid-x Rezeptor selektive Verbindungen |
US5780676A (en) * | 1992-04-22 | 1998-07-14 | Ligand Pharmaceuticals Incorporated | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors |
EP0587377A3 (en) * | 1992-09-10 | 1994-09-21 | Lilly Co Eli | Thiazolidinone derivatives as hypoglycemic agents and for treating alzheimer's disease |
JPH08506323A (ja) | 1992-11-25 | 1996-07-09 | ラ ホヤ キャンサー リサーチ ファウンデーション | Rxrホモダイマー形成ならびに架橋二環式芳香族化合物および調節遺伝子発現におけるそれらの使用 |
DE69508568T2 (de) * | 1994-02-17 | 1999-10-21 | American Home Prod | Substituierte biphenyl-derivate mit phosphodiesterase inhibierender wirkung |
US5691376A (en) * | 1994-02-17 | 1997-11-25 | American Home Products Corporation | Substituted biphenyl derivatives |
JPH09136877A (ja) * | 1995-06-16 | 1997-05-27 | Takeda Chem Ind Ltd | 複素環化合物、その製造法及び用途 |
AU701790B2 (en) | 1995-07-17 | 1999-02-04 | Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) | Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} |
EP0844997A1 (en) | 1996-06-19 | 1998-06-03 | Dr. Reddy's Research Foundation | Novel polymorphic forms of troglitazone having enhanced anti-diabetic activity and a process for their preparation |
PT920312E (pt) * | 1996-07-08 | 2005-04-29 | Galderma Res & Dev | Derivados de adamantilo indutores de apoptose e sua utilizacao como agentes anticancerigenos |
US6355664B1 (en) * | 1997-03-03 | 2002-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease |
CA2300813A1 (en) * | 1997-08-21 | 1999-03-04 | Hiroyuki Odaka | Anti-inflammatory agent |
EP1048659A4 (en) | 1997-11-12 | 2002-11-20 | Inst Med Molecular Design Inc | RETINOID RECEPTOR AGONISTS |
US6262044B1 (en) * | 1998-03-12 | 2001-07-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (PTPASES) |
US7105552B2 (en) * | 1998-05-08 | 2006-09-12 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
US6331633B1 (en) | 1998-05-08 | 2001-12-18 | Calyx Therapeutics Inc. | Heterocyclic analogs of diphenylethylene compounds |
AU743411B2 (en) | 1998-08-21 | 2002-01-24 | Viropharma Incorporated | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
WO2000018748A1 (en) * | 1998-09-30 | 2000-04-06 | Roche Diagnostics Gmbh | Rhodanine derivatives for the treatment and prevention of metabolic bone disorders |
WO2000032598A1 (en) | 1998-12-04 | 2000-06-08 | Structural Bioinformatics Inc. | Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity |
WO2000063196A1 (en) | 1999-04-20 | 2000-10-26 | Novo Nordisk A/S | New compounds, their preparation and use |
US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
US7026334B1 (en) * | 1999-07-26 | 2006-04-11 | Shionogi & Co., Ltd. | Thiazolidine compounds and pharmaceutical compositions exhibiting thrombopoietin receptor agonism |
EP1214305A1 (en) | 1999-08-31 | 2002-06-19 | Maxia Pharmaceuticals, Inc. | Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
CA2355243C (en) | 1999-11-12 | 2009-01-27 | Fujimoto Brothers Co., Ltd. | Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
JP2005506290A (ja) | 2001-03-07 | 2005-03-03 | マキシア・ファーマシューティカルズ・インコーポレイテッド | 癌および他の増殖性疾患を処置するための複素環式誘導体 |
WO2002072543A2 (en) | 2001-03-08 | 2002-09-19 | Maxia Pharmaceuticals, Inc. | Rxr activating molecules |
EP1373240B1 (en) | 2001-03-14 | 2005-06-15 | Eli Lilly And Company | Retinoid x receptor modulators |
US6838442B2 (en) | 2001-04-04 | 2005-01-04 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators |
US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
US6668449B2 (en) * | 2001-06-25 | 2003-12-30 | Micron Technology, Inc. | Method of making a semiconductor device having an opening in a solder mask |
JP2005500379A (ja) | 2001-08-17 | 2005-01-06 | インサイト サンディエゴ インコーポレーテッド | 異脂肪血症および高コレステロール血症を治療するオキシム誘導体 |
JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環 |
TW200304375A (en) | 2001-12-06 | 2003-10-01 | Maxia Pharmaceuticals Inc | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer |
WO2003060078A2 (en) * | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Heterocyclic modulators of nuclear receptors |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
US20050014767A1 (en) | 2003-01-29 | 2005-01-20 | Magnus Pfahl | Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases |
US20050038098A1 (en) | 2003-04-18 | 2005-02-17 | Catherine Tachdjian | Substituted dihydronaphthalene and isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
-
2000
- 2000-08-31 EP EP00961550A patent/EP1214305A1/en not_active Withdrawn
- 2000-08-31 UA UA2002032523A patent/UA74344C2/uk unknown
- 2000-08-31 IL IL14836100A patent/IL148361A0/xx unknown
- 2000-08-31 ES ES00957950T patent/ES2248107T3/es not_active Expired - Lifetime
- 2000-08-31 NZ NZ517993A patent/NZ517993A/en unknown
- 2000-08-31 EP EP00957950A patent/EP1214304B1/en not_active Expired - Lifetime
- 2000-08-31 CA CA002384194A patent/CA2384194A1/en not_active Abandoned
- 2000-08-31 HU HU0203367A patent/HUP0203367A3/hu unknown
- 2000-08-31 AU AU69499/00A patent/AU6949900A/en not_active Abandoned
- 2000-08-31 MX MXPA02002257A patent/MXPA02002257A/es unknown
- 2000-08-31 AU AU73491/00A patent/AU7349100A/en not_active Abandoned
- 2000-08-31 WO PCT/US2000/024348 patent/WO2001016123A1/en not_active Application Discontinuation
- 2000-08-31 CA CA002383347A patent/CA2383347A1/en not_active Abandoned
- 2000-08-31 BR BR0013671-9A patent/BR0013671A/pt not_active IP Right Cessation
- 2000-08-31 EA EA200200311A patent/EA200200311A1/ru unknown
- 2000-08-31 PL PL00354334A patent/PL354334A1/xx not_active Application Discontinuation
- 2000-08-31 WO PCT/US2000/024222 patent/WO2001016122A1/en active IP Right Grant
- 2000-08-31 TW TW089117764A patent/TWI279401B/zh not_active IP Right Cessation
- 2000-08-31 DE DE60022207T patent/DE60022207T2/de not_active Expired - Fee Related
- 2000-08-31 DK DK00957950T patent/DK1214304T3/da active
- 2000-08-31 US US09/652,810 patent/US6515003B1/en not_active Expired - Fee Related
- 2000-08-31 JP JP2001519690A patent/JP2003531104A/ja active Pending
- 2000-08-31 JP JP2001519689A patent/JP2003508391A/ja active Pending
- 2000-08-31 AT AT00957950T patent/ATE302764T1/de not_active IP Right Cessation
- 2000-08-31 CN CN00815079A patent/CN1384825A/zh active Pending
-
2002
- 2002-02-27 NO NO20020960A patent/NO322701B1/no not_active IP Right Cessation
- 2002-03-13 ZA ZA200202064A patent/ZA200202064B/en unknown
- 2002-03-13 ZA ZA200202063A patent/ZA200202063B/en unknown
- 2002-12-19 HK HK02109193A patent/HK1047591A1/xx not_active IP Right Cessation
- 2002-12-31 US US10/334,932 patent/US6765013B2/en not_active Expired - Fee Related
-
2004
- 2004-07-19 US US10/894,411 patent/US6974826B2/en not_active Expired - Fee Related
-
2005
- 2005-08-24 US US11/210,403 patent/US7226940B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102432544A (zh) * | 2011-11-17 | 2012-05-02 | 天津医科大学 | 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用 |
CN102432544B (zh) * | 2011-11-17 | 2014-05-21 | 天津医科大学 | 5-取代苄亚甲基咪唑烷-2,4-二酮类衍生物及其应用 |
CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2,4-二酮在制备ppar激动剂中的应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1384825A (zh) | 亚苄基-噻唑烷二酮及其类似物以及它们在治疗糖尿病中的应用 | |
CN1086387C (zh) | N-(芳氧基烷基)杂芳基呱啶及一杂芳基呱嗪,它们的制备方法以及它们作为药物的应用 | |
CN1252057C (zh) | 用于治疗与paar有关的疾病的噻唑衍生物 | |
CN1638768A (zh) | 调节ppar活性的噻唑和噁唑衍生物 | |
CN1942428A (zh) | Cetp抑制剂 | |
CN1741999A (zh) | 用作GSK-3β抑制剂的哒嗪酮衍生物 | |
CN1009831B (zh) | 杂环氧代-2,3-二氮杂萘基乙酸的制备方法 | |
CN1993124A (zh) | 取代吡唑、含有这种化合物的组合物及其应用 | |
CN1678578A (zh) | 具有抗糖尿病活性的吲哚化合物 | |
CN1173497A (zh) | 含杂环碳酸衍生物 | |
CN1094710A (zh) | 新的环己烷衍生物 | |
CN1017897B (zh) | 二氢吡啶衍生物的制备方法 | |
CN1897936A (zh) | 环状胍、含有这种化合物的组合物及其使用方法 | |
CN1034864C (zh) | 咪唑烷-4-酮和噻唑烷-4-酮的衍生物的制备方法 | |
CN1290700A (zh) | 苯基哌嗪衍生物 | |
CN1026234C (zh) | 用于降血糖的噻唑烷二酮衍生物的制备方法 | |
CN1732002A (zh) | 促进甲状旁腺激素释放的芳基-喹唑啉/芳基-2-氨基-苯基甲酮衍生物 | |
CN1649586A (zh) | 用于治疗糖尿病和其他疾病的杂环酰胺衍生物 | |
CN1087622A (zh) | 取代的环己烷衍生物、其制备方法和治疗疾病的应用 | |
CN1269818C (zh) | 内酰胺化合物及其药物用途 | |
CN1922156A (zh) | 作为钠通道阻断剂的取代的三唑 | |
CN1617854A (zh) | 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用 | |
CN1942434A (zh) | 茚衍生物及其制备方法 | |
CN1061414A (zh) | 单环β-内酰胺类抗生素的杂芳酰基衍生物 | |
CN1774246A (zh) | 用于治疗代谢失调、癌症和其它疾病的取代异色满化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |